Top in allergy/asthma: Oral immunotherapy has limitations; climate change worsens eczema
Click Here to Manage Email Alerts
Adults with food allergies experienced limited success with oral immunotherapy, according to results of a small cohort study.
A third of the patients discontinued treatment within 2 years due to adverse events, which included itching of the mouth or throat, eczema and abdominal pain.
However, the treatment still increased long-term tolerance, and adverse events were mostly mild, researchers said.
It was the top story in allergy/asthma last week.
In another top story, researchers found that climatic hazards associated with greenhouse gas emissions may aggravate atopic dermatitis but also noted that gaps in data persist.
“I think our study highlights the importance of future funding and interdisciplinary initiatives to develop research that can consider multiple climatic factors, integrating basic mechanism with longitudinal outcomes for patients and population-level trends, in diverse populations,” Katrina Abuabara, MD, MA, MSCE, an associate professor of dermatology at the University of California, San Francisco, told Healio.
Read these and more top stories in allergy/asthma below:
Success limited in oral immunotherapy for adults with food allergies
Adults experienced limited success with oral immunotherapy for food allergies, with about half of a cohort halting treatment within 2 years, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Climate change aggravates atopic dermatitis
Climatic hazards associated with greenhouse gas emissions may exacerbate atopic dermatitis, including severity and flares, while increasing its prevalence and related health care utilization, according to a review published in Allergy. Read more.
Most dupilumab use for asthma, CRSwNP categorized as persistent
Researchers characterized the use of dupilumab among a cohort of patients with asthma, chronic rhinosinusitis with nasal polyps or both as persistent in a study published in Annals of Allergy, Asthma & Immunology. Read more.
11.3% of households report drug hypersensitivities
Although 11.3% of households surveyed reported drug hypersensitivities, the prevalence of different hypersensitivities varied significantly, researchers reported. Read more.
Q&A: Joint task force updates anaphylaxis practice parameter
A joint task force has published an updated, evidence-based practice parameter for diagnosing and treating anaphylaxis in Annals of Allergy, Asthma & Immunology. Read more.